We are pleased to announce our business expansion to investment and incubation and the launch of Gemseki Ventures, L.P., a 1.1 billion yen (approximately USD 10 million) fund to incubate and accelerate the growth of start-ups in the life science industry.
Gemseki has been operating the business development platform “Drug Candidate Marketplace” for 3 years since 2017. During this time, we were entrusted with more than 250 projects by domestic and overseas pharmaceutical companies, start-ups, academia, venture capitals, etc., and have carried out licensing, partnering, and M&A activities.
On the other hand, our parent company, Shin Nippon Biomedical Laboratories (SNBL), has accumulated experience and know-how of investment and incubation. Its portfolio companies have been successfully listed not only in the Japanese market but, in the case two of the spun-off companies (WAVE Life Sciences Ltd. and Satsuma Pharmaceutical Inc.) also on the NASDAQ.
While Gemseki conducts around 1000 business consultations annually and thus has established a global network in the life science industry, there remains a lot of interest from start-up companies for us to participate as investors to support their growth by utilizing our group’s accumulated knowledge beyond business development support.
Therefore, we decided to launch our investment activities, and have just completed the formation of Gemseki Ventures L.P., with Gemseki as a general partner and SNBL as a limited partner. Going forward, the investment and incubation business will be added to our business development platform, and we will support the growth and success of our worldwide clients holistically in the life science industry.